Q4 Revenue Rises 2% YoY to ₹1,037 Cr; Operating EBITDA Margin at 25% for Full Year
Syngene International Limited, a contract research, development, and manufacturing organization (CRDMO), announced its Q4 and full-year FY26 results, showing steady revenue growth despite challenges from a key biologics client. Full-year revenue from operations climbed 3% year-on-year to ₹3,739 crore, while Q4 revenue increased 2% YoY to ₹1,037 crore, up 13% quarter-on-quarter.
Financial Snapshot
Syngene’s performance reflected resilience in a cautious biotech funding environment:
Q4 FY26 Highlights (₹ Crore):
- Revenue from Operations: ₹1,037 (up 2% YoY)
- Operating EBITDA: ₹303 (down 12% YoY); Margin: 29%
- PAT (before exceptional items): ₹153 (down 16% YoY); Margin: 14%
- Reported PAT (after exceptional items): ₹148
FY26 Highlights (₹ Crore):
- Revenue from Operations: ₹3,739 (up 3% YoY)
- Operating EBITDA: ₹918 (down 12% YoY); Margin: 25%
- PAT (before exceptional items): ₹380 (down 20% YoY); Margin: 10%
- Reported PAT (after exceptional items): ₹317
- Net cash generated: ₹521 (post capex)
CFO Deepak Jain noted, “Q4 reported growth at 2% and 13% sequentially reflects the ongoing product impact in our largest biologics customer. We generated ₹521 Cr of cash during the year, strengthening our balance sheet.”
The Board recommended a final dividend of ₹1.25 per share, pending shareholder approval.
Leadership Transition and Strategic Focus
In a pivotal shift, Kiran Mazumdar-Shaw transitioned to Executive Chairperson effective April 1, 2026, for five years. Peter Bains will step down as MD & CEO on June 30, 2026, succeeded by Siddharth Mittal from Biocon. New appointees include CHRO Maninder Kapoor Puri and Chief Commercial Officer Abhijit Zutshi (both effective May 1), plus independent directors Vijaya Chandru and Arun Chandavarkar.
Mazumdar-Shaw said, “I look forward to working with the new leadership team to shape our next phase of expansion, investing in AI and digital capabilities that will enhance speed, productivity, and value creation.”
MD & CEO Peter Bains added, “Syngene’s full-year revenue grew 3%. We continued to invest in new capabilities and emerging modalities such as peptides and ADCs.”
Key Business Milestones
- ADC Expansion: Launched ADC discovery lab for high-throughput handling of potent compounds, completing an end-to-end platform from discovery to GMP manufacturing.
- Audits & Accreditations: Passed 14 audits in Q4 (85 for FY26); earned GCP-NABL accreditation.
- Sustainability: Ranked top 10 in S&P Global Sustainability Yearbook 2026; named ‘Industry Mover’.
Syngene will host an earnings call on April 30 at 2 PM IST (dial-in: +91 22 6280 1279; webcast link available on www.syngeneintl.com).
Despite margin pressures from biologics and new facility costs, Syngene’s diversified model and investments position it for growth in outsourced life sciences services.
